A novel MDM2/p53 inhibitor in patients with advanced solid tumors – ESMO Open

ESMO Open (The Open Access journal of European Society for Medical Oncology) shared a post on X:

”Out in ESMO Open:

First-in-human phase 1 trial of a novel MDM2/p53 inhibitor (alrizomadlin) in patients with advanced solid tumors.

Authors: Xing Zhang, X. Wen, R. Peng, D. Yang, Li Zhang, Yifan Zhai.

Evidence of strong MDM2 engagement, restoration of p53 function and early clinical activity.”

Source: ESMO Open/X

The European Society for Medical Oncology (ESMO) represents over 35,000 oncology professionals across 172 countries and is a key resource for oncology education and information. ESMO’s primary mission is to enhance the quality of cancer care, spanning prevention, diagnosis, palliative care, and patient follow-up. It focuses on educating doctors, cancer patients, and the general public about best practices and the latest advancements in oncology, and advocates for equal access to optimal cancer care for all patients.